Document is current
Any future updates will be listed below
-
Authors
Lane, Roger M.
Darreh-Shori, Taher
Junge, Candice
Li, Dan
Yang, Qingqing
Edwards, Amanda L.
Graham, Danielle L.
Moore, Katrina
Mummery, Catherine J.
-
Funding
Funding for this research was provided by:
Biogen, Boston, United States
- License Information
-
More Information
Article History
Received: 19 December 2023
Accepted: 26 March 2024
First Online: 9 April 2024
Declarations
:
: The trial (NCT03186989) was conducted in accordance with Good Clinical Practice Guidelines of the International Council for Harmonisation, and according to the ethical principles outlined in the Declaration of Helsinki.Patients provided written, informed consent at the time of recruitment. The study was approved by the institutional review board or independent ethics committee at each investigational site; see supplementary materials (Additional file 2).
: Not applicable.
: RML, CJ, DL, QY, KM: Employees of, and holders of stock/stock options in, Ionis. TDS: No conflicts of interest. ALE, DLG: Employees of, and holders of stock/stock options in, Biogen. CJM: Supported by the NIHR Biomedical Research Centre at UCLH; received honoraria for patient and clinician educational activities related to AD from Biogen, Lilly, and Peerview; received institutional consulting/advisory board fees from Biogen, Roche, Eli Lilly, Prevail, Alnylam, Alector, Eisai, WAVE, and Ionis; served as a site-investigator for several clinical trials sponsored by Ionis and Biogen.
